ImmunoCellular Therapeutics, PEG Ratio

The latest PEG ratio for IMUC is 4.8. That is below the Healthcare sector average of 12.15. Investors often review this figure alongside ImmunoCellular Therapeutics,'s historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, IMUC currently prints 4.8 for PEG ratio, while the sector average sits near 12.15. That is roughly 60.5% below the sector mean. Large gaps often invite a closer look at ImmunoCellular Therapeutics,'s growth, margins, and balance sheet.

A PEG ratio of 4.8 for ImmunoCellular Therapeutics, is not 'good' or 'bad' on its own. Compare it with the peer average (12.15) and with IMUC's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting IMUC's PEG ratio (4.8), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack ImmunoCellular Therapeutics,'s PEG ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.